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Sef Is a Spatial Regulator
for Ras/MAP Kinase Signaling
of activated ERK remains in the cytoplasm and phos-
phorylates cytoplasmic ERK targets, such as RSK (Stur-
gill et al., 1988). Nuclear translocation of ERK is required
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for growth factor-induced gene expression and reinitia-Department of Cell and Developmental Biology
tion of cell proliferation (Brunet et al., 1999; PouyssegurGraduate School of Biostudies
and Lenormand, 2003). Recent reports have shown that,Kyoto University
in addition to MEK, phosphoprotein enriched in astro-Sakyo-ku, Kyoto 606-8502
cytes 15 kDa (PEA-15) is also able to act as a cyto-Japan
plasmic anchor for ERK. PEA-15, which also contains
NES, binds both ERK and RSK2 constitutively and thus
retains both ERK and RSK2 in the cytoplasm of
Summary astrocytes (Formstecher et al., 2001; Vaidyanathan and
Ramos, 2003), although how this anchoring is regulated
Spatiotemporal control of the Ras/ERK MAP kinase remains to be answered.
signaling pathway is among the key mechanisms for A series of recent reports has demonstrated that a
regulating a wide variety of cellular processes. In this significant portion of Ras is localized and activated at
study, we report that human Sef (hSef), a recently iden- the Golgi apparatus and the endoplasmic reticulum (ER)
tified inhibitor whose action mechanism has not been in response to EGF stimulation (Choy et al., 1999; Chiu
fully defined, acts as a molecular switch for ERK sig- et al., 2002; Bivona and Philips, 2003; Bivona et al., 2003).
naling by specifically blocking ERK nuclear transloca- Activation of Ras at the Golgi apparatus is dependent on
tion without inhibiting its activity in the cytoplasm. the Src/PLC/Ca2/RasGRP1 signaling pathway (Bivona
Thus, hSef binds to activated forms of MEK, inhibits and Philips, 2003; Bivona et al., 2003), which is distinct
the dissociation of the MEK-ERK complex, and blocks from the Grb2/SOS pathway at the plasma membrane.
Thus, like activation of Ras on different subcellular com-nuclear translocation of activated ERK. Consequently,
partments, activation of the downstream MEK-ERKhSef inhibits phosphorylation and activation of the nu-
pathway may also occur near or at various compart-clear ERK substrate Elk-1, while it does not affect
ments, including the Golgi and ER.phosphorylation of the cytoplasmic ERK substrate
Recent studies have identified several inhibitors forRSK2. Downregulation of endogenous hSef by hSef
Ras/ERK signaling, and among them Sprouty and SpredsiRNA enhances the stimulus-induced ERK nuclear
are found to regulate the strength or duration of signalingtranslocation and the activity of Elk-1. These results
(Hacohen et al., 1998; Casci et al., 1999; Kramer et al.,thus demonstrate that hSef acts as a spatial regulator
1999; Wakioka et al., 2001; Wong et al., 2002; Hanafusafor ERK signaling by targeting ERK to the cytoplasm.
et al., 2002; Sasaki et al., 2003; Kato et al., 2003). Most
recently, Sef (similar expression to fgf genes) was identi-
Introduction fied in zebrafish as an inhibitor of Ras/MAPK-mediated
FGF signaling (Tsang et al., 2002; Furthauer et al., 2002).
The Ras/ERK MAP kinase signaling pathway regulates Sef has a putative signal peptide and a putative trans-
membrane domain and thus is believed to be a trans-a vast array of cellular responses to extracellular stimuli
membrane protein (Tsang et al., 2002; Furthauer et al.,(Sturgill and Wu, 1991; Nishida and Gotoh, 1993; Rob-
2002; Lin et al., 2002; Kawakami et al., 2003). Sef hasinson and Cobb, 1997; Lewis et al., 1998; Hunter, 2000;
been identified in other vertebrates and thus is thoughtSchlessinger, 2000; Chang and Karin, 2001). Extracellu-
to be a conserved inhibitor of FGF signaling (Tsang etlar stimuli, such as growth factors, induce sequential
al., 2002; Furthauer et al., 2002; Lin et al., 2002; Niehrsactivation of three protein kinases, Raf, MEK, and ERK,
and Meinhardt, 2002; Kawakami et al., 2003; Preger etin the Ras/ERK signaling pathway. MEK always localizes
al., 2004). Vertebrate Sef is expressed in highly restrictedto the cytoplasm by its nuclear export signal (NES) se-
patterns in early stages of embryos, and its expressionquence (Fukuda et al., 1996), and cytoplasmic localiza-
pattern is similar to the expression patterns of fgf genestion of ERK in quiescent cells appears to be achieved
such as fgf3, fgf8, and fgf17 and sprouty members suchby its binding to the N-terminal region of MEK (Fukuda
as sprouty2 and sprouty4 (Tsang et al., 2002; Furthaueret al., 1997). In response to stimulation, MEK phosphory-
et al., 2002; Lin et al., 2002; Kawakami et al., 2003). Inlation of ERK induces the activation of ERK and its disso-
Xenopus embryos, injection of zebrafish Sef (zSef)ciation from the MEK-ERK complex (Adachi et al., 1999).
mRNA was found to inhibit FGF-induced expression ofDissociated, activated ERK then translocates from the
Xbra, a panmesodermal marker (Tsang et al., 2002).cytoplasm to the nucleus (Chen et al., 1992; Gonzalez
There have been, however, contradicting reports con-et al., 1993; Lenormand et al., 1993; Khokhlatchev et al.,
cerning the action point of Sef (Furthauer et al., 2002;1998), where ERK phosphorylates and activates several
Kovalenko et al., 2003; Xiong et al., 2003; Yang et al.,nuclear ERK targets, including transcription factors,
2003; Preger et al., 2004). In the first report, zSef wassuch as Elk-1 (Treisman, 1996). On the other hand, part
shown to inhibit phosphorylation of ERK induced by
either constitutively active Ras or constitutively active
MEK, suggesting that Sef acts downstream of or at MEK*Correspondence: l50174@sakura.kudpc.kyoto-u.ac.jp
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Figure 1. The Action Point of Sef in Ras/
ERK Signaling
(A) hSef constructs used in this study. SP,
signal peptide (black); putative extracellular
domain (blue); TM, putative transmembrane
domain (yellow); juxtamembrane domain
(red); IL17R-like, similar to IL17 receptor do-
main (green).
(B) For luciferase assays, HEK293 cells were
transfected with pFA-Elk-1, pFR-luciferase
plasmids, and increasing amounts of hSef
constructs and treated with 50 ng/ml basic
FGF before the activity was measured. Error
bars indicate SEM (n  3).
(C) Effect of hSef, hSef Y330F, and mSpred1
on active Ras (V12Ras)- or active MEK (SDSE-
MEK)-induced activation of Elk-1.
(Furthauer et al., 2002). In agreement with this, there are Our detailed analyses here demonstrate that hSef
binds to activated MEK specifically, inhibits the dissoci-reports indicating that human Sef (hSef) is able to reduce
phosphorylation of ERK but not phosphorylation of MEK ation of the MEK-ERK complex, and thus blocks nuclear
translocation of activated ERK without inhibiting the ac-(Yang et al., 2003; Preger et al., 2004). In contrast, other
reports argue that Sef inhibits FGF signaling at the level tivity of ERK in the cytoplasm. Furthermore, our results
show that hSef localizes mainly to the Golgi apparatusof FGF receptor, as Sef, by binding to FGF receptor,
is able to inhibit FGF-induced phosphorylation of FGF in unstimulated cells, and after stimulation part of hSef
translocates to the plasma membrane region. In stimu-receptor and subsequent phosphorylation of FRS2, a
substrate of FGF receptor (Kovalenko et al., 2003). Fur- lated cells, activated MEK and activated ERK colocalize
with hSef in both the Golgi apparatus and plasma mem-thermore, Sef was reported to inhibit FGF- or constitu-
tively active FGF receptor-induced phosphorylation of brane regions. Then, hSef inhibits the stimulus-depen-
dent phosphorylation of the nuclear ERK substrate Elk-1,ERK but not active Ras-induced phosphorylation of ERK
(Kovalenko et al., 2003; Xiong et al., 2003) or active MEK- whereas hSef does not inhibit phosphorylation of the
cytoplasmic ERK substrate RSK2. Remarkably, hSefinduced phosphorylation of ERK (Xiong et al., 2003).
Consistent with these observations, there is a report siRNA experiments have clearly demonstrated that down-
regulation of endogenous hSef enhances the stimulus-showing that mouse Sef is able to specifically inhibit
FGF-induced phosphorylation of ERK without inhibiting dependent ERK nuclear translocation and the activation
of Elk-1 and thus upregulates the expression of SRE-PDGF-BB-, EGF-, or calf serum-induced phosphoryla-
tion of ERK in NIH3T3 cells (Kovalenko et al., 2003). In regulated ERK target genes, such as c-fos, egr1, and
junB. All these results demonstrate that hSef is a regula-contrast, however, overexpression of hSef was reported
to inhibit not only FGF-induced differentiation of PC12 tor for intracellular localization of the Ras/ERK pathway
and acts as a stimulus-dependent spatial regulator forcells but also NGF-induced differentiation (Xiong et al.,
2003). Thus, molecular mechanisms of actions of Sef ERK signaling by blocking signaling to the nucleus and
allowing signaling to the cytoplasm.have been controversial.
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Figure 2. Binding of hSef to Activated Forms of MEK Is Required for the Inhibitor Activity of hSef
(A) C2C12 cells were transfected with Flag-hSef and HA-MEK (wild-type [WT], SDSE-MEK [DE], SASA-MEK [SASA]) with or without V12Ras.
HA-MEK constructs that bound to Flag-hSef were detected by immunoprecipitation (IP) with an antibody against Flag followed by immunoblot-
ting with an antibody against HA.
(B and C) hSef binds to phosphorylated MEK in response to FGF (B) or EGF (C) stimulation.
(D) C2C12 cells were transfected with HA-hSef and Flag-MEK and stimulated with 15% fetal bovine serum (FCS) for indicated times.
(E) Binding of hSef constructs to SDSE-MEK. Only hSef 356 did not bind to SDSE-MEK.
(F and G) Effect of hSef constructs and mSpred1 on FGF- or EGF-induced activation of Elk-1 in HEK293 cells (F) or HeLa cells (G). Only hSef
356 failed to inhibit the activation of Elk-1. Experiments were carried out as in Figure 1B.
Results and Discussion is replaced by phenylalanine (Figure 1A). In a reporter
assay measuring the transcription activity of Elk-1, a
nuclear target of ERK, full-length hSef and hSef Y330FhSef Inhibits Ras/ERK Signaling Downstream
of or at MEK but not hSef 356 or hSef 356 Y330F, inhibited FGF-
induced activation of Elk-1 in a dose-dependent mannerTo examine the action mechanisms of hSef, we con-
structed various C-terminal deletion mutants and a YF (Figure 1B), suggesting that a C-terminal half but not a
conserved tyrosine residue is important for the inhibitormutant in which a putative regulatory tyrosine residue
(Y330, corresponding to Y329 of zSef [Tsang et al., 2002]) activity of hSef. This result is different from the previous
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Figure 3. hSef Colocalizes with Activated
MEK at the Golgi Apparatus and Ruffling
Plasma Membrane Regions
(A) Subcellular distribution of Myc-hSef and
GM130 or -adaptin in COS7 cells.
(B and C) Subcellular localization of Myc-hSef
and HA-MEK (B) or Myc-hSef and phosphory-
lated MEK (C) in COS7 cells. COS7 cells were
transfected with Myc-hSef and HA-MEK and
stimulated with EGF for 5 min. Cells of bot-
tommost of each panel are treated with dig-
itonin. Arrowheads indicate ruffling plasma
membrane regions.
one for zSef (Tsang et al., 2002), which might result from cells (see Supplemental Figure S1A at http://www.
developmentalcell .com/cgi/content/full/7/1/33/differences in the assay system and species of Sef that
were used. As hSef inhibited FGF-induced activation of DC1). Then, we examined the effect of hSef on the FGF-
induced S phase entry of quiescent cells by using theElk-1, we next examined whether expressed hSef inhib-
its the expression of SRE-regulated ERK target genes, BrdU incorporation assay. When GFP and control vec-
tors were microinjected into serum-starved NIH3T3such as egr1. In NIH3T3 cells, the percentage of Egr1-
positive cells, which was measured by an anti-Egr1 anti- cells, the percentage of BrdU-positive cells was in-
creased from 6% in unstimulated cells to 41% in FGF-body, was increased from 8% in unstimulated cells to
70% in FGF-stimulated cells. When hSef was expressed, stimulated (for 16 hr) cells. When GFP and hSef-express-
ing vectors were microinjected, the percentage of BrdU-the percentage of Egr1-positive cells in hSef-express-
ing ones was decreased to 32% in FGF-stimulated positive cells was decreased to 23% in FGF-stimulated
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Figure 4. hSef Does Not Inhibit Phosphorylation of ERK
(A) HEK293 cells were transfected with the indicated combinations of cDNAs, stimulated with FGF (50 ng/ml) for the indicated times, and
analyzed by immunoblotting with indicated antibodies.
(B and C) C2C12 cells were transfected with the indicated combinations of cDNAs and analyzed by immunoprecipitation with an antibody
against Myc followed by immunoblotting with an antibody against phosphoERK1/2.
(D) Colocalization of hSef with phosphorylated ERK1/2 at the Golgi apparatus and ruffling plasma membrane region in response to EGF
stimulation. COS7 cells were transfected with Myc-hSef, HA-MEK, and HA-ERK. Arrowheads indicate ruffling plasma membrane regions.
cells (see Supplemental Figure S1A at http://www. upstream of MEK in response to FGF or EGF stimulation
(Wakioka et al., 2001; Kato et al., 2003). In agreementdevelopmentalcell.com/cgi/content/full/7/1/33/DC1).
Thus, hSef could inhibit expression of ERK target genes with the previous report (Wakioka et al., 2001), mSpred1
inhibited active Ras-induced activation of Elk-1 but notand suppress the growth factor-induced cell cycle pro-
gression. active MEK-induced activation in our reporter assay
(Figure 1C). Under the same conditions, hSef inhibitedThere have been contradicting reports concerning the
action point of Sef, downstream of MEK (Furthauer et active MEK-induced activation as well as active Ras-
induced activation of Elk-1 (Figure 1C), indicating thatal., 2002; Yang et al., 2003; Preger et al., 2004) or at the
level of FGF receptor (Kovalenko et al., 2003; Xiong hSef inhibits Ras/ERK signaling downstream of or at
MEK. Consistent with this, hSef is able to inhibit EGF-et al., 2003). To address this, we used mouse Spred1
(mSpred1) as a control, because mSpred1 was found induced activation of Elk-1 as well as FGF-induced acti-
vation (see Figure 2G).to inhibit Ras/ERK signaling downstream of Ras and
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Binding of hSef to Activated Forms of MEK Is nonstimulating conditions (Figure 3B). After EGF treat-
ment for 5 min, however, part of hSef translocated toRequired for the Inhibitor Activity of hSef
We considered the possibility that the action point of the plasma membrane region (Figure 3B), and part of
MEK translocated to the same plasma membrane regionhSef might be at MEK itself. To test this idea, we exam-
ined a possible binding between hSef and MEK. Immu- and to the Golgi apparatus (Figure 3B). Our time-lapse
microscopy experiments showed that part of hSef,noprecipitation experiments have shown that hSef is
able to bind to activated forms of MEK. Under nonstimu- which localized on membranous vesicles, could move
constitutively (data not shown). After EGF stimulation,lating conditions, hSef bound to the constitutively active
mutant of MEK (SDSE-MEK, a phosphorylation-mimick- the part of hSef on vesicles may rapidly translocate to
the plasma membrane. The precise mechanism and theing mutant) but not to wild-type MEK (Figure 2A). When
active Ras was coexpressed, hSef became bound to mode of this translocation are unknown at present. To
confirm more clearly that hSef colocalizes with MEKMEK (Figure 2A). Even in the presence of active Ras,
a nonphosphorylatable (i.e., nonactivatable) mutant of at the Golgi apparatus, we used digitonin treatment.
Treatment with the weak detergent digitonin perforatesMEK (SASA-MEK) did not bind to hSef significantly (Fig-
ure 2A). In addition, when cells were stimulated with the plasma membrane, but the nucleus and membra-
nous organelles, such as the Golgi apparatus, remainFGF, EGF, or 15% fetal bovine serum, hSef bound to
MEK in a stimulus-dependent manner (Figures 2B–2D). relatively intact (Adam et al., 1990; Matsubayashi et al.,
2001). In digitonin-treated cells, colocalization of hSefIn all these experiments, the extent of the binding be-
tween hSef and MEK correlated very well with the extent and MEK on the Golgi after EGF stimulation was more
clearly seen (Figure 3B, bottom). Immunofluorescenceof phosphorylation of MEK (Figures 2A–2D). These re-
sults taken together indicate that hSef binds to acti- with an anti-phosphoMEK antibody showed localization
of phosphorylated, activated MEK at the Golgi appara-vated MEK.
We then tested various deletion mutants of hSef for tus and the plasma membrane regions with hSef after
EGF stimulation (Figure 3C). Again, in digitonin-treatedtheir ability to bind to MEK and their inhibitor activity
against Elk-1. In the binding assay, wild-type hSef, hSef cells, colocalization of phosphorylated, activated MEK
with hSef at the Golgi apparatus was more clearly seen.565, hSef 443, and hSef 395 but not hSef 356
bound to active MEK significantly (Figure 2E). Corre- Recent reports have shown that part of Ras is localized
and activated at the Golgi apparatus in response to EGFspondingly, wild-type hSef, hSef 565, hSef 443, and
hSef 395 but not hSef 356 inhibited FGF- or EGF- stimulation (Choy et al., 1999; Chiu et al., 2002; Bivona
and Philips, 2003; Bivona et al., 2003). hSef at the Golgiinduced activation of Elk-1 in a dose-dependent manner
(Figures 2F and 2G). Thus, there is a very good correla- could bind well to MEK, which is activated downstream
of Ras at the Golgi. Thus, activated MEK colocalizestion in these hSef mutants between the ability to bind
to activated MEK and the inhibitor activity against Elk-1. with hSef in stimulated cells at both the Golgi and plasma
membrane regions.
hSef Colocalizes with Activated MEK at the Golgi
Apparatus and Plasma Membrane Regions
To confirm the stimulus-dependent interaction of hSef hSef Does Not Inhibit Phosphorylation of ERK
and Colocalizes with Phosphorylated ERKwith MEK, we determined subcellular distribution of hSef
and MEK. Sef is shown to have a putative signal peptide as Well as Phosphorylated MEK
To determine subsequent events after the stimulus-and a transmembrane domain (Tsang et al., 2002; Fur-
thauer et al., 2002; Lin et al., 2002; Kawakami et al., 2003) dependent binding of hSef to activated MEK, we then
examined whether hSef inhibits phosphorylation and ac-and is thus believed to be a transmembrane protein.
Biochemical fractionation experiments showed that ex- tivation of ERK. We thought that hSef would inhibit phos-
phorylation of ERK, because hSef inhibits strongly thepressed Sef is present in membrane fractions (see Sup-
plemental Figure S1B at http://www.developmentalcell. activation of Elk-1, a well-known ERK substrate. Rather
surprisingly, however, hSef did not inhibit FGF-stimu-com/cgi/content/full/7/1/33/DC1). When expressed in
COS7 cells, the majority of hSef localized to the Golgi lated phosphorylation of ERK or MEK in HEK293 cells
(Figure 4A). Under the same conditions, mSpred1apparatus, as shown by colocalization with GM130 or
-adaptin (Figure 3A). As MEK localizes to the cytoplasm strongly inhibited phosphorylation of ERK and MEK (Fig-
ure 4A). Essentially the same results were obtained indiffusely due to its nuclear export signal (Fukuda et
al., 1996), hSef and MEK do not colocalize at all under EGF-stimulated HeLa cells and EGF-stimulated COS7
Figure 5. hSef Inhibits the Dissociation of MEK-ERK Complex and Nuclear Translocation of ERK
(A) hSef WT and hSef Y330F but not hSef 356 inhibit the dissociation of the MEK-ERK complex. C2C12 cells were transfected with the
indicated combinations of cDNAs and analyzed by immunoprecipitation with an antibody against HA followed by immunoblotting with antibodies
against Myc and Flag.
(B) hSef binds to the N-terminal deletion mutant of MEK. C2C12 cells were transfected with HA-hSef and Myc-MEK (WT or N) with or without
V12Ras. Myc-MEK constructs that bound to HA-hSef were detected by immunoprecipitation with an antibody against HA followed by
immunoblotting with an antibody against Myc (left). MEK N did not bind to ERK (right).
(C) hSef WT but not hSef 356 inhibits nuclear translocation of ERK. HeLa cells were transfected with the indicated combinations of cDNAs
and stimulated with EGF for 10 min.
(D–F) HeLa cells were transfected with indicated combinations of cDNAs and stimulated with active Ras or FGF for the indicated times.
Subcellular localization of Myc-Elk-1 or Myc-NES-Elk-1 is shown.
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cells (data not shown). Moreover, while mSpred1 inhib- MEK, inhibits the stimulus-dependent dissociation of
the MEK-ERK complex without inhibiting MEK phos-ited active Ras-induced phosphorylation of ERK, hSef
did not (Figure 4B). In addition, hSef and mSpred1 were phorylation of ERK, and blocks nuclear translocation of
activated ERK. If this scenario is correct, hSef wouldunable to inhibit active MEK-induced phosphorylation
of ERK (Figure 4C). Correspondingly, hSef did not inhibit inhibit phosphorylation of ERK substrates in the nucleus
without inhibiting phosphorylation of cytoplasmic ERKthe active Ras- or active MEK-induced activation of the
kinase activity of ERK (see Supplemental Figure S1C at substrates. Consistent with the observation that hSef
but not hSef 356 inhibits the stimulus-dependent acti-http://www.developmentalcell.com/cgi/content/full/7/
1/33/DC1). Immunofluorescence experiments con- vation of Elk-1 (see Figures 2F and 2G), hSef but not
hSef 356 inhibited FGF-, EGF-, or active Ras-stimu-firmed that hSef does not inhibit phosphorylation of ERK
(Figure 4D). In COS7 cells, where hSef, MEK, and ERK lated phosphorylation of Elk-1 on serine 383 (Figure 5D;
data not shown). In contrast, when Elk-1 was expressedwere overexpressed, phosphorylated ERK as well as
phosphorylated MEK was detected after EGF treatment in the cytoplasm by fusing the NES sequence of MEK
to Elk-1 (NES-Elk-1), the stimulus-dependent phosphor-for 5 min and colocalized with hSef at the Golgi appara-
tus and the ruffling plasma membrane regions (Figure ylation of NES-Elk-1 was not inhibited significantly by
hSef (Figure 5E, top). Cytoplasmic localization of NES-4D; see also Figure 3C). These observations demon-
strate that hSef does not inhibit phosphorylation/activa- Elk-1 was confirmed by immunofluorescence (Figure 5E,
bottom). RSK2 is a well-known ERK substrate in thetion of ERK and suggest the possibility that hSef would
retain activated ERK in the cytoplasm to prevent it from cytoplasm (Sturgill et al., 1988) and has been shown to
undergo autophosphorylation on serine 386 after ERKentering the nucleus.
phosphorylation (Dalby et al., 1998). Our data show that
hSef did not inhibit FGF-dependent autophosphoryla-hSef Inhibits the Dissociation of the MEK-ERK
tion of RSK2, whereas mSpred1 did (Figure 5F). Thus,Complex and Thus Blocks Nuclear
hSef inhibits phosphorylation of nuclear ERK substratesTranslocation of ERK
and the expression of ERK target genes without inhib-To address this possibility, we first examined whether
iting phosphorylation of cytoplasmic ERK substrates byhSef inhibits the stimulus-dependent dissociation of the
specifically blocking ERK nuclear translocation.MEK-ERK complex, because previous studies have
shown that MEK acts as a cytoplasmic anchor for ERK
under nonstimulating conditions and that, in response hSef siRNA Treatment Enhances the Nuclear
to stimulation, MEK phosphorylation of ERK induces Translocation of ERK, the Activity of Elk-1,
the dissociation of the MEK-ERK complex, resulting in and the Expression of ERK Target Genes
nuclear translocation of dissociated, activated ERK in EGF-Stimulated Cells without Altering
(Chen et al., 1992; Gonzalez et al., 1993; Lenormand et Phosphorylation of ERK
al., 1993; Fukuda et al., 1996, 1997; Adachi et al., 1999). Finally, we performed hSef siRNA treatment in HeLa-S3
Coimmunoprecipitation assays showed that wild-type cells. Treatment with either of the two siRNAs (si1 and
hSef and hSef Y330F, which is also active as an inhibitor, si2) specifically downregulated endogenous hSef ex-
inhibited the active MEK-induced dissociation of the pression, but treatment with a control siRNA (cont.), a
MEK-ERK complex, whereas hSef 356, which is inac- si1 reverse sequence, did not (Figure 6A). Both of the
tive as an inhibitor, did not inhibit the dissociation (Figure Sef siRNA treatments (si1 and si2) enhanced markedly
5A). They showed further that wild-type hSef and hSef EGF-, active Ras-, or active MEK-induced activation of
Y330F but not hSef 356 bound to the MEK-ERK com- Elk-1 activity (Figure 6B; data not shown) without alter-
plex (Figure 5A). None of the hSef constructs inhibited ing significantly phosphorylation and activation of ERK
phosphorylation of ERK (Figure 5A) or its kinase activ- (Figure 6C; data not shown). Moreover, the hSef siRNA
ity (see Supplemental Figure S1C at http://www. treatment enhanced markedly EGF-stimulated ERK nu-
developmentalcell .com/cgi/content/full/7/1/33/ clear translocation (Figure 6D). For example, the siRNA
DC1). These results are consistent with the immunofluo- treatment increased the percentage of the cells that
rescence data shown above. Our domain analysis using showed strong nuclear accumulation of ERK at 10 min
an N-terminal deletion mutant of MEK (MEK N) demon- after EGF stimulation from 21% (cont.) to 35% (si1) or
strated that an N-terminal region (residues 1 through 32% (si2). Furthermore, the hSef siRNA treatment en-
32) of MEK, which is an essential region for binding to hanced significantly the expression level of c-fos, egr1,
ERK (Figure 5B, right; Fukuda et al., 1997), is dispens- and junB, which are well-known ERK target genes, after
able for binding to hSef (Figure 5B, left). This is consis- EGF stimulation (Figure 6E). In contrast, the siRNA treat-
tent with the idea that hSef, activated MEK, and ERK ment did not affect EGF-dependent phosphorylation of
form a complex. RSK2 significantly (Figure 6F). These observations fur-
Then, we examined whether hSef inhibits ERK nuclear ther support our idea that hSef acts as a specific inhibitor
translocation. To this end, we used HeLa cells, in which of ERK signaling to the nucleus by targeting ERK to
EGF stimulation is able to induce strong nuclear translo- the cytoplasm.
cation of ERK (Figure 5C, top). Expression of wild-type
hSef but not hSef 356almost completely inhibited EGF-
stimulated nuclear translocation of ERK (Figure 5C, bot- hSef Acts as a Spatial Regulator for Ras/ERK
Signaling by Targeting ERK to the Cytoplasmtom). Essentially the same results were obtained in EGF-
stimulated COS7 cells (data not shown). All these results Ras/ERK MAP kinase signaling regulates a vast array
of cellular responses to extracellular stimuli, such astaken together indicate that hSef binds to activated
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Figure 6. hSef siRNA Treatment Enhances the Nuclear Translocation of ERK, the Activity of Elk-1, and the Expression of ERK Target Genes
in EGF-Stimulated Cells without Altering Phosphorylation of ERK
(A) hSef was specifically downregulated in cells by hSef siRNA treatment (si1 or si2). Control siRNA is a reverse sequence of si1. HeLa-S3
cells were treated with either of the hSef siRNAs or a control siRNA, and expression of endogenous hSef was analyzed by RT-PCR using
G3PDH as control (left). HeLa-S3 cells expressing Myc-tagged hSef were treated as above, and the cell extracts were prepared and subjected
to immunoblotting with antibodies against Myc or -tubulin as control (right).
(B) hSef siRNA treatment enhances EGF- or active MEK-induced activation of Elk-1 in HeLa-S3 cells. Luciferase activity was measured as in
Figure 1B.
(C) hSef siRNA treatment does not affect EGF- or active MEK-induced phosphorylation of ERK.
(D) HeLa-S3 cells were treated with hSef siRNA and incubated in serum-free medium for 24 hr. Then, the cells were treated with or without
EGF for 10 min and stained with an antibody against ERK2. More than 200 cells were classified in terms of location of endogenous ERK2,
and each percentage of cells in which staining in the nucleus was stronger than that in the cytoplasm is shown (left). Representative images
of the cells are shown (right).
(E) hSef siRNA treatment enhances the induction of mRNA of the SRE-regulated genes c-fos, egr1, and junB. HeLa-S3 cells were treated with
hSef siRNA or control siRNA. After the cells were incubated in serum-free medium for 24 hr, the cells were incubated with or without EGF
(30 nM) for the indicated times. The relative levels of each of the mRNAs were determined by RT-PCR analysis. Each value was normalized
to human G3PDH, and the value of control siRNA at EGF treatment for 0 hr of each gene was set to 1. Error bars indicate SEM (n  3). At
0.1 or 1 nM EGF stimulation, the hSef siRNA treatment enhanced the expression of these genes to roughly the same extent (about 1.5- to
2-fold enhancement) as at 30 nM EGF (data not shown).
(F) hSef siRNA treatment does not affect EGF-induced phosphorylation of RSK2. Numbers below the upper panel represent relative intensities
of phosphorylation of RSK2. At later time points (at 0.5 or 1.0 hr), no phosphorylation of RSK2 was detected in either control or hSef siRNA-
treated cells (data not shown).
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Figure 7. A Model for the Action of Sef
In the absence of Sef, activated MEK phos-
phorylates ERK, and the phosphorylated ERK
dissociates from the MEK-ERK complex.
Then, activated ERK phosphorylates RSK2 in
the cytoplasm or translocates to the nucleus
and phosphorylates Elk-1 (left). Sef binds to
activated MEK, inhibits the dissociation of the
MEK-ERK complex, and retains activated
ERK at the Golgi apparatus or plasma mem-
brane. Thus, Sef specifically inhibits ERK nu-
clear translocation without inhibiting its activ-
ity in the cytoplasm (right).
anti-mouse or rabbit IgG from Molecular Probes; Cy5-labeled goatgrowth factors (Sturgill and Wu, 1991; Nishida and Go-
anti-rabbit IgG from Amersham Pharmacia Biotech. Cells were lysedtoh, 1993; Robinson and Cobb, 1997; Lewis et al., 1998;
in a buffer comprising 20 mM HEPES (pH 7.5), 100 mM NaCl, 1.5 mMHunter, 2000; Schlessinger, 2000; Chang and Karin,
MgCl2, 1 mM EGTA, 10 mM Na4P2O7, 1% Nonidet P-40, 2 mM dithi-2001). It is generally believed that spatiotemporal control othreitol, 1 mM vanadate, 1 mM PMSF, 1% aprotinin, and 10%
of this pathway is a key factor for determining the speci- glycerol. Cell lysates were subjected to immunoprecipitation and
immunoblotting with the indicated antibodies.ficity of cellular responses (Chang and Karin, 2001;
Formstecher et al., 2001; Bivona and Philips, 2003; Pouys-
segur and Lenormand, 2003; Vaidyanathan and Ramos, Cell Cultures and Transfection
C2C12 cells, COS7 cells, HEK293 cells, HeLa-S3 cells, and HeLa2003). Recently, several inhibitors for Ras/ERK signaling
cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)have been identified, and among them Sprouty and re-
containing 15%, 10%, 10%, and 10% fetal bovine serum (FBS) andlated molecules are found to regulate the strength or
10% calf serum (CS), respectively. HEK293 cells were cultured on
duration of signaling (Hacohen et al., 1998; Casci et al., plates coated with collagen. We divided these cells between 35 mm
1999; Kramer et al., 1999; Wakioka et al., 2001; Wong and 60 mm dishes at 1 105 and 3 105 cells per dish, respectively.
et al., 2002; Hanafusa et al., 2002; Sasaki et al., 2003; After 18 hr, the cells were transfected by using Lipofectamine Plus
reagent (Invitrogen) for C2C12 cells and COS7 cells, LipofectamineKato et al., 2003). Our results here show that hSef is a
2000 (Invitrogen) for HEK293 cells, and FuGENE6 (Roche) for HeLaregulator for intracellular localization of this pathway
cells according to the manufacturer’s protocol.and acts to restrict ERK activity to the cytoplasm. Thus,
spatiotemporal control of ERK signaling is finely regu-
Cell Staining and Digitonin Treatmentlated by multiple factors. A remarkable feature of the
Cells were fixed by adding formaldehyde (to a final concentration
hSef action is that its interaction with the Ras/ERK sig- of 3.7%) directly to the cell culture medium and then permeabilized
naling pathway is switched on by the activation of this with 0.5% Triton X-100 in PBS for 5 min. The cells were incubated
pathway, as hSef specifically binds to activated MEK. with indicated primary antibodies at room temperature for 1 hr and
then with the appropriate secondary antibodies at room temperatureThus, hSef acts as a signaling-dependent regulator for
for 1 hr. Cells were finally mounted in Mowiol and examined usingthis pathway (Figure 7). The next challenges may include
a laser scanning confocal microscope (Bio-Rad) or Zeiss Axiophot2.elucidation of molecular mechanisms regulating hSef
In some cases, after EGF treatment, cells were treated with digitonin
expression and function. (20 g/ml; Calbiochem) for 5 min on ice. Then, cells were incubated
in 4% paraformaldehyde in PBS for 15 min at 37C and then incu-
Experimental Procedures bated in methanol for 20 min at 	20C.
Molecular Cloning and Plasmid Construction
siRNAThe full-length cDNA of hSef (GenBank accession number
RNA oligonucleotides (21 nucleotides) homologous to hSef wereAX350979) was isolated from HEK293 cells by PCR. All hSef con-
designed as follows. si1, forward, 5
-GUCGG AGGGA AGACAstructs were prepared by PCR and ligated into pCS2 containing a
GUGCT T; reverse, 5
-GCACU GUCUU CCCUC CGACT T. si2, for-Myc, HA, or Flag tag. All tags were added to the C terminus of
ward, 5
-GCAUG UGAUU GCUGA CGCCT T; reverse, 5
-GGCGUhSef constructs.
CAGCA AUCAC AUGCT T. Control siRNA, forward, 5
-CGUGA
CAGAA GGGAG GCUGT T; reverse, 5
-CAGCC UCCCU UCUGULuciferase Assay
CACGT T. Cells were treated with annealed siRNAs by the use ofCells were treated for 15–20 hr with or without 50 ng/ml basic FGF
Oligofectamine (Invitrogen). By using Alexa Fluor 594 fusion siRNA,or 30 nM EGF, and the luciferase activity in cell lysates was mea-
we estimated that siRNA transfection efficiency was around 90%.sured by using the luciferase assay system (Promega, Madison, WI)
in a Berthold Lumat LB 9507 luminometer. We normalized the rela-
tive luciferase activity to the activity of coexpressed -galactos- RT-PCR by Using Light Cycler
idase. Total RNA was reverse transcribed into cDNA by using M-MLV re-
verse transcriptase (Invitrogen) with oligo random hexamers. Pre-
pared cDNA was purified and subjected to quantitative PCR analysisAntibodies, Immunoprecipitation, and Immunoblotting
Antibodies were purchased as follows: antibodies against phos- by using Light Cycler (Roche Diagnostics) with SYBR Green PCR
Kit (Qiagen). The primers for the PCR analysis were as follows.phoERK1/2, phosphoMEK1/2, phosphoElk-1, and phospho-p90RSK
from Cell Signaling technology; antibodies against Myc, HA, Egr1, For human G3PDH, forward, 5
-TGGGC TACAC TGAGC ACCAG
GTGGT; reverse, 5
-CATGT GGGCC ATGAG GTCCA CCAC. For hu-and ERK1/2 from Santa Cruz Biotechnology; antibodies against
Flag, -adaptin, and -tubulin from Sigma; an antibody against man c-fos, forward, 5
-CCAGG GCTGG CGTTG TGAAG; reverse,
5
-CTTGG AGTGT ATCAG TCAGC. For human egr1, forward, 5
-GM130 from Biosciences; Alexa Fluor 488 goat anti-mouse or rabbit
IgG, Alexa Fluor 546 goat anti-rabbit IgG, and Alexa Fluor 594 goat CAGCA CCTTC AACCC TCAGG; reverse, 5
-GTAAC TGGTC TCCAC
hSef Provides Spatial Control for ERK Signaling
43
CAGCA. For human junB, forward, 5
-CAGCT ACTTT TCTGG Hacohen, N., Kramer, S., Sutherland, D., Hiromi, Y., and Krasnow,
M.A. (1998). sprouty encodes a novel antagonist of FGF signalingTCAGG; reverse, 5
-GTGTA GGCGT CGTCG TGATC.
that patterns apical branching of the Drosophila airways. Cell 92,
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